Pyxis Oncology to present MICVO phase 1 data at EORTC symposium
Tweet Send to a Friend
Pyxis Oncology, Inc. (NASDAQ: PYXS) announced it will present phase 1 monotherapy data for micvotabart pelidotin (MICVO) in a late-breaking ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




